AtheroGenics to Present at Lehman Brothers Global Healthcare Conference March 18, 2008
11 Marzo 2008 - 2:31PM
Marketwired
ATLANTA, GA , a pharmaceutical company focused on the treatment
of chronic inflammatory diseases, today announced that Russell M.
Medford, M.D., Ph.D., President and Chief Executive Officer, will
be presenting a company overview and update at the upcoming 11th
Annual Lehman Brothers Global Healthcare Conference on Tuesday,
March 18, 2008, at 3:45 p.m. Eastern Daylight Time at the Loews
Miami Beach Hotel in South Beach, Florida.
A live audio webcast of the presentation will be available on
the AtheroGenics Investor Relations Events website at
http://www.atherogenics.com. A replay of the presentation will be
available on the Company's website approximately twenty-four hours
after the presentation and will be archived for thirty days.
About AtheroGenics
AtheroGenics is focused on the discovery, development and
commercialization of novel drugs for the treatment of chronic
inflammatory diseases, including diabetes and coronary heart
disease (atherosclerosis). AtheroGenics has completed patient
enrollment in ANDES (AGI-1067 as a Novel Anti-Diabetic Agent
Evaluation Study), a Phase III clinical trial evaluating its oral
anti-inflammatory and antioxidant lead candidate, AGI-1067, in
patients with diabetes. In addition, the Company has other clinical
and preclinical anti-inflammatory compounds, including AGI-1096, an
oral agent for the prevention of organ transplant rejection. For
more information about AtheroGenics, please visit
http://www.atherogenics.com.
CONTACTS: AtheroGenics, Inc. Donna L. Glasky Corporate
Communications 678-336-2517 Email Contact Media Inquiries Jayme
Maniatis / Dana Conti Schwartz Communications, Inc. 781-684-0770
Email Contact Investor Inquiries Lilian Stern Stern Investor
Relations, Inc. 212-362-1200 Email Contact
Grafico Azioni Atherogenics (NASDAQ:AGIX)
Storico
Da Mag 2024 a Giu 2024
Grafico Azioni Atherogenics (NASDAQ:AGIX)
Storico
Da Giu 2023 a Giu 2024
Notizie in Tempo Reale relative a Atherogenics (MM) (NASDAQ): 0 articoli recenti
Più AtheroGenics, Inc. Articoli Notizie